2 results
Approved WMOCompleted
Primary:To evaluate if progression-free survival from randomization to progression or death during second-line therapy (total PFS) of sorafenib followed by pazopanib is non-inferior compared to pazopanib followed by sorafenib.Secondary:1. Time from…
Approved WMORecruiting
Cost-utility and cost-effectiveness of eye-screening in home healthcare in reducing eye complaints from a societal perspective and its health consequences will be investigated over 1 year. A cluster randomized controlled trial (RCT), including an…